Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper

M. Destoop, P. Mohr, F. Butlen, P. Kéri, J. Samochowiec, L. De Picker, A. Fiorillo, KPC. Kuypers, G. Dom

. 2025 ; 68 (1) : e3. [pub] 20250110

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010286

BACKGROUND: Recent years show an exponential increased interest ("renaissance") in the use of psychedelics for the treatment of mental disorders and broader. Some of these treatments, such as psilocybin for depression, are in the process of formal regulation by regulatory bodies in the US (FDA) and Europe (EMA), and as such on the brink of real-world implementation. In the slipstream of these developments increasing commercial initiatives are taking shape. The European Psychiatric Association (EPA) acknowledges both the therapeutic potential of psychedelic substances and the challenges for both research and clinical implementation. Steps need to be taken toward a well-balanced policy based upon sound scientific evidence and research, aiming at safe, ethical responsible integration of psychedelic therapy available for all patients who can potentially benefit. METHODS: In this EPA policy paper, we highlight the potential benefits, and also the challenges of psychedelic treatments, which can be relevant for the future real-world implementation of these treatments. RESULTS: In addition to an overview of the current evidence and hypotheses of working mechanisms of psychedelic treatment, this policy paper specifically highlights the importance of the psychosocial components of the treatment as well as the ethical and professional aspects playing a role in real-world implementation. CONCLUSIONS: Four recommendations are formulated for further research and clinical implementation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010286
003      
CZ-PrNML
005      
20250429134613.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1192/j.eurpsy.2024.1806 $2 doi
035    __
$a (PubMed)39791347
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Destoop, M $u Collaborative Antwerp Psychiatric Research Institute (CAPRI), University of Antwerp, Antwerp, Belgium $u Multiversum Psychiatric Hospital, Boechout, Belgium
245    10
$a Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper / $c M. Destoop, P. Mohr, F. Butlen, P. Kéri, J. Samochowiec, L. De Picker, A. Fiorillo, KPC. Kuypers, G. Dom
520    9_
$a BACKGROUND: Recent years show an exponential increased interest ("renaissance") in the use of psychedelics for the treatment of mental disorders and broader. Some of these treatments, such as psilocybin for depression, are in the process of formal regulation by regulatory bodies in the US (FDA) and Europe (EMA), and as such on the brink of real-world implementation. In the slipstream of these developments increasing commercial initiatives are taking shape. The European Psychiatric Association (EPA) acknowledges both the therapeutic potential of psychedelic substances and the challenges for both research and clinical implementation. Steps need to be taken toward a well-balanced policy based upon sound scientific evidence and research, aiming at safe, ethical responsible integration of psychedelic therapy available for all patients who can potentially benefit. METHODS: In this EPA policy paper, we highlight the potential benefits, and also the challenges of psychedelic treatments, which can be relevant for the future real-world implementation of these treatments. RESULTS: In addition to an overview of the current evidence and hypotheses of working mechanisms of psychedelic treatment, this policy paper specifically highlights the importance of the psychosocial components of the treatment as well as the ethical and professional aspects playing a role in real-world implementation. CONCLUSIONS: Four recommendations are formulated for further research and clinical implementation.
650    _2
$a lidé $7 D006801
650    12
$a halucinogeny $x terapeutické užití $7 D006213
650    12
$a duševní poruchy $x farmakoterapie $7 D001523
650    _2
$a psilocybin $x terapeutické užití $x farmakologie $7 D011562
650    _2
$a psychiatrie $7 D011570
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mohr, P $u Clinical Department, National Institute of Mental Health, Klecany, Czech Republic $u Third School of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000298513271 $7 xx0054512
700    1_
$a Butlen, F $u Office for Neurological and Psychiatric Disorders, European Medicines Agency, Amsterdam, The Netherlands $u Institut Gustave Roussy, Psycho-Oncology Unit, Interdisciplinary Department for the Organization of Patient Pathways, Cancer Campus, Grand Paris, France $u Université Paris-Saclay, UVSQ, Inserm, CESP, Villejuif, France $1 https://orcid.org/0000000283052089
700    1_
$a Kéri, P $u Global Alliance of Mental Illness Advocacy Networks-Europe (GAMIAN-Europe), Brussels, Belgium
700    1_
$a Samochowiec, J $u Pomeranian Medical University in Szczecin, Szczecin, Poland $1 https://orcid.org/000000031438583X
700    1_
$a De Picker, L $u Collaborative Antwerp Psychiatric Research Institute (CAPRI), University of Antwerp, Antwerp, Belgium $u University Psychiatric Hospital, Duffel, Belgium $1 https://orcid.org/0000000268830559
700    1_
$a Fiorillo, A $u Department of Psychiatry, University of Campania Luigi Vanvitelli, Naples, Italy $1 https://orcid.org/0000000269260762
700    1_
$a Kuypers, K P C $u Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands $1 https://orcid.org/0000000176343809
700    1_
$a Dom, G $u Collaborative Antwerp Psychiatric Research Institute (CAPRI), University of Antwerp, Antwerp, Belgium $u Multiversum Psychiatric Hospital, Boechout, Belgium $1 https://orcid.org/0000000164920429
773    0_
$w MED00001658 $t European psychiatry $x 1778-3585 $g Roč. 68, č. 1 (2025), s. e3
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39791347 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134608 $b ABA008
999    __
$a ok $b bmc $g 2311568 $s 1247367
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 68 $c 1 $d e3 $e 20250110 $i 1778-3585 $m European psychiatry $n Eur Psychiatry $x MED00001658
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace